Floating dosage forms: an in vivo study demonstrating prolonged gastric retention.

Gastroretentive dosage forms have potential for use as controlled-release drug delivery systems. The use of floating dosage forms (FDFs) is one method to achieve prolonged gastric residence times (GRTs), providing opportunity for both local and systemic drug action. Multiple-unit systems avoid the 'all-or-nothing' gastric emptying nature of single-unit systems. A freeze-dried calcium alginate multiple-unit FDF has been developed which demonstrated favourable in vitro floating characteristics. The aim of this study was to investigate the in vivo behaviour of this system compared to a multiple-unit non-floating dosage form manufactured from identical material. The study was performed in seven healthy volunteers, who swallowed the radiolabelled formulations after a standard breakfast. Transit was monitored by gamma-scintigraphy and subjects were maintained in the fed state. Prolonged GRTs of over 5.5 h were achieved in all subjects for the floating formulations, which remained high up in the stomach for the whole of the test period. In contrast, the non-floating beads displayed short GRTs, with a mean onset emptying time of 1 h. The results of this study suggest that, in the fed state, this FDF has potential for sustained drug delivery for either local or systemic purposes.

[1]  A. Moes Gastroretentive dosage forms. , 1993, Critical reviews in therapeutic drug carrier systems.

[2]  C. J. Gray,et al.  Retention of insulin in alginate gel beads. , 1988, Biotechnology and bioengineering.

[3]  J. Newton,et al.  Gastrointestinal transit of pellets of differing size and density , 1993 .

[4]  M. Cooreman,et al.  Local gastric and serum amoxicillin concentrations after different oral application forms , 1993, Antimicrobial Agents and Chemotherapy.

[5]  Masaki Ichikawa,et al.  A new multiple-unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustained-release characteristics. , 1991, Journal of pharmaceutical sciences.

[6]  J. Timmermans,et al.  The cutoff size for gastric emptying of dosage forms. , 1993, Journal of pharmaceutical sciences.

[7]  L. C. Feely,et al.  Gastrointestinal transit of non-disintegrating tablets in fed subjects , 1989 .

[8]  R. D. Moss,et al.  Microencapsulation of living cells and tissues. , 1981, Journal of pharmaceutical sciences.

[9]  E. Doelker,et al.  Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery , 1996 .

[10]  R. Ducret,et al.  Evaluation of the gastric retention properties of a cross-linked polymer coated tablet versus those of a non-disintegrating tablet , 1991 .

[11]  C. T. Rhodes,et al.  Optimization of Sotalol Floating and Bioadhesive Extended Release Tablet Formulations , 1995 .

[12]  J. Fell,et al.  Development of a gastroretentive dosage form. , 1996 .

[13]  Alan Parr,et al.  Evaluation of the effect of food and specific gravity of tablets on gastric retention time , 1987 .